JP2006522062A - 神経学的障害の処置のための抗癲癇剤を含む組み合わせ - Google Patents
神経学的障害の処置のための抗癲癇剤を含む組み合わせ Download PDFInfo
- Publication number
- JP2006522062A JP2006522062A JP2006504970A JP2006504970A JP2006522062A JP 2006522062 A JP2006522062 A JP 2006522062A JP 2006504970 A JP2006504970 A JP 2006504970A JP 2006504970 A JP2006504970 A JP 2006504970A JP 2006522062 A JP2006522062 A JP 2006522062A
- Authority
- JP
- Japan
- Prior art keywords
- combination
- combination according
- administered
- treatment
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001961 anticonvulsive agent Substances 0.000 title claims abstract description 11
- 230000003556 anti-epileptic effect Effects 0.000 title claims description 4
- 229960003965 antiepileptics Drugs 0.000 title claims description 4
- 208000012902 Nervous system disease Diseases 0.000 title abstract description 3
- 208000025966 Neurological disease Diseases 0.000 title abstract description 3
- 206010015037 epilepsy Diseases 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 150000003839 salts Chemical group 0.000 claims description 14
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 8
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical group C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 8
- 229960000623 carbamazepine Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229960001816 oxcarbazepine Drugs 0.000 claims description 6
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims description 6
- 238000009097 single-agent therapy Methods 0.000 claims description 6
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims description 5
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 5
- 229940049706 benzodiazepine Drugs 0.000 claims description 5
- 150000001557 benzodiazepines Chemical class 0.000 claims description 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 5
- 150000001469 hydantoins Chemical class 0.000 claims description 5
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 5
- 229960000604 valproic acid Drugs 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 3
- 229940053180 other antiepileptics in atc Drugs 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 125000001118 alkylidene group Chemical group 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 claims 4
- 208000014617 hemorrhoid Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 description 33
- 230000000694 effects Effects 0.000 description 12
- 230000037396 body weight Effects 0.000 description 10
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 150000003857 carboxamides Chemical class 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 5
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 5
- HPHUVLMMVZITSG-LURJTMIESA-N levetiracetam Chemical compound CC[C@@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-LURJTMIESA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 4
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 4
- 229960003529 diazepam Drugs 0.000 description 4
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 4
- QZULPCPLWGCGSL-UHFFFAOYSA-N irampanel Chemical compound CN(C)CCOC1=CC=CC=C1C1=NC(C=2C=CC=CC=2)=NO1 QZULPCPLWGCGSL-UHFFFAOYSA-N 0.000 description 4
- 229960001848 lamotrigine Drugs 0.000 description 4
- 229960004002 levetiracetam Drugs 0.000 description 4
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 4
- 229960002695 phenobarbital Drugs 0.000 description 4
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 229960004394 topiramate Drugs 0.000 description 4
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 4
- KOZCGZMZXXVHCF-GGMCWBHBSA-N (3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid hydrate hydrochloride Chemical compound O.Cl.C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C KOZCGZMZXXVHCF-GGMCWBHBSA-N 0.000 description 3
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 3
- AEFZZVQZPBFFPN-UHFFFAOYSA-N 7-[4-[(4-carboxyphenyl)carbamoyloxymethyl]imidazol-1-yl]-3-oxo-6-(trifluoromethyl)-4h-quinoxaline-2-carboxylic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC(=O)OCC1=CN(C=2C(=CC=3NC(=O)C(C(O)=O)=NC=3C=2)C(F)(F)F)C=N1 AEFZZVQZPBFFPN-UHFFFAOYSA-N 0.000 description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 3
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 description 3
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229960003120 clonazepam Drugs 0.000 description 3
- 229960002767 ethosuximide Drugs 0.000 description 3
- 229960002870 gabapentin Drugs 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960004391 lorazepam Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229960002036 phenytoin Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 229960002393 primidone Drugs 0.000 description 3
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical class [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 3
- 229960002573 sultiame Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940035305 topamax Drugs 0.000 description 3
- 229960005318 vigabatrin Drugs 0.000 description 3
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
- CBHCOCUJJQDHSR-UHFFFAOYSA-N 7-acetyl-5-(4-aminophenyl)-8-methyl-9h-[1,3]dioxolo[4,5-h][2,3]benzodiazepine-8-carbonitrile Chemical compound C12=CC=3OCOC=3C=C2CC(C#N)(C)N(C(=O)C)N=C1C1=CC=C(N)C=C1 CBHCOCUJJQDHSR-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000000228 antimanic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 2
- -1 ferbamate Chemical compound 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229950010390 irampanel Drugs 0.000 description 2
- 229960003729 mesuximide Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- SEPKUNXLGWMPHL-UHFFFAOYSA-N quinoxaline-2,3-dione Chemical compound C1=CC=CC2=NC(=O)C(=O)N=C21 SEPKUNXLGWMPHL-UHFFFAOYSA-N 0.000 description 2
- IEWVBTBLBYYUTR-UHFFFAOYSA-M sodium;2-[[5-[4-(dimethylsulfamoyl)phenyl]-8-methyl-2-oxo-7,9-dihydro-6h-pyrrolo[3,2-h]isoquinolin-3-yl]amino]oxy-4-hydroxybutanoate Chemical compound [Na+].C1=CC(S(=O)(=O)N(C)C)=CC=C1C1=CC2=C(NOC(CCO)C([O-])=O)C(=O)N=C2C2=C1CCN(C)C2 IEWVBTBLBYYUTR-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229950004608 talampanel Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YUKARLAABCGMCN-PKLMIRHRSA-N tiagabine hydrochloride Chemical compound Cl.C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C YUKARLAABCGMCN-PKLMIRHRSA-N 0.000 description 2
- FPXVCCSOTAQPIV-UHFFFAOYSA-N 4-(8-chloro-2-methyl-11h-imidazo[1,2-c][2,3]benzodiazepin-6-yl)aniline Chemical compound C12=CC(Cl)=CC=C2CC2=NC(C)=CN2N=C1C1=CC=C(N)C=C1 FPXVCCSOTAQPIV-UHFFFAOYSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- RPBDCDQMCRHNLM-UHFFFAOYSA-N C1=NNC=C2C=CC=CC2=C1 Chemical compound C1=NNC=C2C=CC=CC2=C1 RPBDCDQMCRHNLM-UHFFFAOYSA-N 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229960003472 felbamate Drugs 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940084457 gabitril Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940062717 keppra Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940072170 lamictal Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229940106773 sabril Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002410 tiagabine hydrochloride Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0307860.7A GB0307860D0 (en) | 2003-04-04 | 2003-04-04 | Organic compounds |
| PCT/EP2004/003518 WO2004087161A1 (en) | 2003-04-04 | 2004-04-02 | Combinations comprising anti-epileptic drugs for the treatment of neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006522062A true JP2006522062A (ja) | 2006-09-28 |
| JP2006522062A5 JP2006522062A5 (enExample) | 2007-05-17 |
Family
ID=9956223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504970A Pending JP2006522062A (ja) | 2003-04-04 | 2004-04-02 | 神経学的障害の処置のための抗癲癇剤を含む組み合わせ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060194766A1 (enExample) |
| EP (1) | EP1620103A1 (enExample) |
| JP (1) | JP2006522062A (enExample) |
| CN (1) | CN100546581C (enExample) |
| AU (1) | AU2004226825B2 (enExample) |
| BR (1) | BRPI0409170A (enExample) |
| CA (1) | CA2521274A1 (enExample) |
| GB (1) | GB0307860D0 (enExample) |
| MX (1) | MXPA05010707A (enExample) |
| WO (1) | WO2004087161A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| EP2164489A2 (en) * | 2007-07-13 | 2010-03-24 | Eisai R&D Management Co., Ltd. | Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain |
| WO2009015244A1 (en) * | 2007-07-23 | 2009-01-29 | Synosia Therapeutics | Rufinamide for the treatment of post-traumatic stress disorder |
| PL3061821T3 (pl) | 2009-07-22 | 2020-01-31 | PureTech Health LLC | Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| CN112789042A (zh) | 2018-09-28 | 2021-05-11 | 卡鲁娜治疗学有限公司 | 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001502681A (ja) * | 1996-10-24 | 2001-02-27 | ノバルティス アクチエンゲゼルシャフト | 置換アミノアルカンホスホン酸 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB864536A (en) * | 1957-11-06 | 1961-04-06 | Sapos S A Lab | ª‡-ethyl-phenylacetylurea |
| GB1028234A (en) * | 1964-01-06 | 1966-05-04 | Ici Ltd | New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives |
| WO1989005642A1 (en) * | 1987-12-22 | 1989-06-29 | Ferkany John W | Dextrorphan potentiator for anticonvulsant composition and method |
| US5095033A (en) * | 1991-03-01 | 1992-03-10 | Laboratoires Biocodex | Method for treating epilepsy |
| IT1261808B (it) * | 1993-07-06 | 1996-06-03 | Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi | |
| WO1998017692A1 (en) * | 1996-10-19 | 1998-04-30 | University Of Wales, Bangor | Preparation of chemically reactive polysaccharides |
| US6306909B1 (en) * | 1997-03-12 | 2001-10-23 | Queen's University At Kingston | Anti-epileptogenic agents |
| CN1265889A (zh) * | 1999-03-06 | 2000-09-13 | 王学勇 | 一种治疗癫痫病的药物 |
| IL149530A0 (en) * | 1999-12-01 | 2002-11-10 | Ucb Sa | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
| US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
| KR20050044396A (ko) * | 2001-11-12 | 2005-05-12 | 노파르티스 아게 | 정동 및 주의력 장애 및 신경병성 통증 치료용 의약제조에 사용하기 위한 모노히드록시카르바마제핀 |
-
2003
- 2003-04-04 GB GBGB0307860.7A patent/GB0307860D0/en not_active Ceased
-
2004
- 2004-04-02 CN CNB2004800092188A patent/CN100546581C/zh not_active Expired - Fee Related
- 2004-04-02 CA CA002521274A patent/CA2521274A1/en not_active Abandoned
- 2004-04-02 EP EP04725366A patent/EP1620103A1/en not_active Withdrawn
- 2004-04-02 WO PCT/EP2004/003518 patent/WO2004087161A1/en not_active Ceased
- 2004-04-02 MX MXPA05010707A patent/MXPA05010707A/es not_active Application Discontinuation
- 2004-04-02 AU AU2004226825A patent/AU2004226825B2/en not_active Ceased
- 2004-04-02 JP JP2006504970A patent/JP2006522062A/ja active Pending
- 2004-04-02 BR BRPI0409170-1A patent/BRPI0409170A/pt not_active IP Right Cessation
- 2004-04-02 US US10/550,381 patent/US20060194766A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001502681A (ja) * | 1996-10-24 | 2001-02-27 | ノバルティス アクチエンゲゼルシャフト | 置換アミノアルカンホスホン酸 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004226825B2 (en) | 2007-08-16 |
| BRPI0409170A (pt) | 2006-04-11 |
| MXPA05010707A (es) | 2005-12-12 |
| WO2004087161A1 (en) | 2004-10-14 |
| CA2521274A1 (en) | 2004-10-14 |
| GB0307860D0 (en) | 2003-05-14 |
| AU2004226825A1 (en) | 2004-10-14 |
| EP1620103A1 (en) | 2006-02-01 |
| US20060194766A1 (en) | 2006-08-31 |
| CN100546581C (zh) | 2009-10-07 |
| CN1767832A (zh) | 2006-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007517901A (ja) | 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物 | |
| EP2146706B1 (en) | Use of dimiracetam in the treatment of chronic pain | |
| JP2009539996A (ja) | 腎機能障害を持つ個体における利尿改善方法 | |
| CA2540102C (en) | A combination of candesartan and rosuvastatin for the treatment of atherosclerosis | |
| JP2006522062A (ja) | 神経学的障害の処置のための抗癲癇剤を含む組み合わせ | |
| NZ543109A (en) | Method of improved diuresis in individuals with impaired renal function | |
| AU2004290890B2 (en) | Combinations comprising AMPA receptor antagonists for the treatment of schizophrenia | |
| JP3598116B2 (ja) | 遅発性ジスキネジアの治療用医薬組成物とその利用 | |
| JP7265526B2 (ja) | てんかん治療剤 | |
| KR20050121236A (ko) | 치매 환자에서 초조 증상을 치료하기 위한 카르바마제핀유도체의 용도 | |
| CA2568436A1 (en) | Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor | |
| WO2005049042A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of tinnitus | |
| WO2005049041A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of anxiety disorders | |
| WO2005094797A2 (en) | Use of ampa-receptor antagonists for treating dementia | |
| WO2005049039A1 (en) | Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders | |
| WO2005039594A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of myopia | |
| WO2005039593A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of neuropathic pain | |
| HK1187244A (en) | Use of dimiracetam in the treatment of chronic pain | |
| EP1932529A1 (en) | Method of improved diuresis in individuals with impaired renal function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070322 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070322 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100427 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101116 |